Therapeutically, these patients may also benefit from peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE, which delivers targeted beta-emitting radiation to SSTR2-expressing tumor cells [51]. Here, SSTR2 is linked to neoplasm.